miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.

Yue D, Qin X

DOI: 10.1038/s41417-018-0031-4
Published: 2019 Feb
Container: Cancer gene therapy
Publisher: Not recorded
Open access: unknown

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41417-018-0031-4,
  title = {miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.},
  author = {Yue D and Qin X},
  year = {2019},
  journal = {Cancer gene therapy},
  doi = {10.1038/s41417-018-0031-4},
  url = {https://doi.org/10.1038/s41417-018-0031-4}
}

RIS

TY  - JOUR
TI  - miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
AU  - Yue D
AU  - Qin X
PY  - 2019
JO  - Cancer gene therapy
DO  - 10.1038/s41417-018-0031-4
UR  - https://doi.org/10.1038/s41417-018-0031-4
ER  -

APA

D, Y., & X, Q. (2019). miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.. Cancer gene therapy. https://doi.org/10.1038/s41417-018-0031-4

Source records

pubmed · retrieved 2026-11-10T14:48:03.003Z